Exploring regulatory data sets of the Comirnaty vaccine - Third part
A summary of posts
In the 11 subseries of three posts, we defined effectiveness outcomes that we thought were important.
how they are defined and reported in the package inserts
and how they are reported in the regulatory documentation
We noted that the definitions were unsatisfactory, death from or with Covid had no definition, and the incidence of disease in the placebo arm was very low (even with a leg up from misreporting of PCR), undermining the whole emergency narrative (as noted by switched on reader).
In 12a, we went back on the harms in package inserts which were inconsistently reported and with difficult-to-compare incidence estimates.
Finally, we thought we’d lift the gloom by inserting a little bit of old geezer humour in
Here is a summary slide to help you navigate through it all:
We will continue to monitor what is going on. However, the bottom line is that due diligence has not been carried out. The consequences will become clearer as time passes.
Remember that two old geezers wrote the series, …
Keep reading with a 7-day free trial
Subscribe to Trust the Evidence to keep reading this post and get 7 days of free access to the full post archives.